A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.

Publication Type:

Journal Article

Source:

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, Volume 15, Issue 8, p.1014-21 (2012)

Keywords:

Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Colonic Neoplasms, Cost-Benefit Analysis, Humans, Life Expectancy, Markov Chains, Neoplasm Recurrence, Local, Neoplasm Staging, Prognosis, Quality-Adjusted Life Years, United States

Abstract:

Uncertainty exists regarding appropriate and affordable use of adjuvant chemotherapy in stage II colon cancer (T3, proficient DNA mismatch repair). This study aimed to estimate the effectiveness and costs from a US societal perspective of a multigene recurrence score (RS) assay for patients recently diagnosed with stage II colon cancer (T3, proficient DNA mismatch repair) eligible for adjuvant chemotherapy.